Careful patient selection for wearable cardioverter-defibrillator (WCD) use is crucial, but unfortunately very little information from randomised controlled trials is available to guide clinical decision-making.
The programmed death-1 (PD-1) pathway serves as a checkpoint to limit T-cell mediated immune responses. Blocking the PD-1 receptor on T cells with monoclonal antibodies results in T-cell activation and proliferation and can induce a potent immunotherapeutic antitumour effect.
Improving patient safety in hospitals demands effective and reliable monitoring of adverse events (AEs). The most common method of assessing AEs is retrospective chart review; the Global Trigger Tool is a promising chart review method.
SMW is an international peer-reviewed medical journal, established in 1871.
Public Service Open Access is also known als Diamond or Platinum OA.
Newsletter for advertisers
Swiss Medical Weekly EMH Swiss Medical Publishers Ltd. Farnsburgerstrasse 8 CH-4132 Muttenz Tel. +41 (0)61 467 85 55 Fax +41 (0)61 467 85 56 e-mail: Editorial office
EMH MediaSchweizerische ÄrztezeitungSwiss Medical ForumPrimary and Hospital CareCardiovascular MedicineSwiss Archives of Neurology, Psychiatry and PsychotherapySynapseSwiss Medical Informatics